Clinical trial · no report yet · Phase 3
MAESTRA 3
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
- NCT07797283 ↗
- Not yet recruiting
- Incyte Corporation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Double-Blind, Randomized, Controlled Study of INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1 (MAESTRA 3)
- Phase
- Phase 3
- Status
- Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- INCB123667; Bevacizumab; Placebo
- Arms
- Treatment Group A (TGA) · Experimental
- Treatment Group B (TGB) · Experimental
- Enrollment
- 590 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) by BICR
- Sponsor
- Incyte Corporation
- Start
- Dec 1, 2026 (estimated)
- Primary completion
- May 1, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT07797283 · updated Oct 2, 2026